Lincomycin Hydrochloride Tablets

This product has high antibacterial activity against common aerobic Gram-positive bacteria, such as Staphylococcus aureus (including those resistant to penicillin G), Staphylococcus epidermidis, beta-hemolytic Streptococcus, viridans Streptococcus and Streptococcus pneumoniae. It has good antibacterial effect on anaerobic bacteria, including Clostridium tetani, Corynebacterium diphtheriae and Clostridium perfringens. It is inactive against Gram-negative bacteria such as enterococci, meningococci, Neisseria gonorrhoeae and Haemophilus influenzae, as well as fungi. There is no cross-resistance between this product and penicillin, chloramphenicol, cephalosporins and tetracyclines, and there is partial cross-resistance with macrolides. This product acts on the 50S subunit of the ribosome of sensitive bacteria, preventing the extension of the peptide chain, thereby inhibiting the protein synthesis of bacterial cells. It is generally an antibacterial agent, but at high concentrations, it also has a bactericidal effect on certain bacteria. The median lethal dose (LD50) of this product is 214 mg/kg for intravenous injection in mice and 4000 mg/kg for oral administration; the oral administration in rats is 4000 mg/kg.

The main ingredient of this product is lincomycin hydrochloride.

This product is a white tablet or sugar-coated tablet; it appears white after removing the coating.

This product is suitable for respiratory tract infections, skin and soft tissue infections, female reproductive tract infections, pelvic infections and abdominal infections caused by sensitive Staphylococcus, Streptococcus, Streptococcus pneumoniae and anaerobic bacteria. The latter two diseases can be used alone or in combination with other antibacterial drugs according to the situation. In addition, for patients with indications for the use of penicillin, such as patients who are allergic to penicillin or are not suitable for penicillin, this product can be used as an alternative drug.

Adults: 1.5-2g (3-4 tablets) per day, divided into 3-4 times orally; children: 30-60mg/kg per day, divided into 3-4 times orally; infants under 4 weeks old should not take this product. This product should be taken on an empty stomach

1. Gastrointestinal reactions: symptoms such as nausea, vomiting, abdominal pain, diarrhea, etc.; severe cases include abdominal cramps, abdominal tenderness, severe diarrhea (watery or purulent), accompanied by fever, abnormal thirst and fatigue (pseudomembranous enterocolitis); diarrhea, enteritis and pseudomembranous enterocolitis may occur in the early stage of medication or several weeks after discontinuation of medication. 2. Blood system: leukopenia, neutropenia, neutropenia and thrombocytopenia may occur occasionally, and aplastic anemia is rare. 3. Allergic reactions: rash, itching, etc. may be seen, urticaria, angioedema and serum sickness reactions may be seen occasionally, and there are rare reports of epidermal excoriation, bullous dermatitis, erythema multiforme and S-J syndrome. 4. There are occasional reports of jaundice caused by oral administration of this product.

It is contraindicated in patients with a history of hypersensitivity to lincomycin and clindamycin.

Precautions for children: It is not suitable for infants under 1 month old. Precautions for pregnancy and lactation: This product can be concentrated in the fetal liver after passing through the placenta. Although there are no reports of problems in human use, the use of this product in pregnant women requires a full weighing of the pros and cons. This product can be secreted into breast milk, so lactating women should also use it with caution. If it must be used, breastfeeding should be suspended. Precautions for the elderly: Elderly people with serious underlying diseases are prone to adverse reactions such as diarrhea or pseudomembranous colitis, and need to be closely observed during medication.

1. It can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory depression or paralysis (apnea). Caution should be taken when used in combination during or after surgery. Treatment with anticholinesterase drugs or calcium salts is expected to be effective. 2. When used in combination with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay, this product may cause pseudomembranous colitis with severe watery diarrhea during the course of treatment or even a few weeks after the course of treatment. Because it can delay the excretion of colonic endotoxins, thereby causing prolonged and aggravated diarrhea, antiperistaltic antidiarrheal drugs should not be used in combination. When this product is used in combination with antidiarrheal drugs containing white clay, the absorption of the former will be significantly reduced, so the two should not be taken at the same time, and a certain interval (at least 2 hours) is required. 3. This product has a neuromuscular blocking effect. When used in combination with anti-myasthenic drugs, the latter will weaken the effect on skeletal muscles. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted when used in combination. 4. Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the latter from binding to the bacterial ribosome 50S subunit. In vitro tests show that this product has an antagonistic effect with erythromycin, so this product should not be used in combination with chloramphenicol or erythromycin. 5. When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may lead to prolonged respiratory depression or respiratory paralysis (apnea) due to the cumulative phenomenon, so the patient must be closely observed or monitored. 6. This product can enhance the effect of neuromuscular blocking drugs, and the two should be avoided in combination.

Keep sealed.

0.25g (calculated as C18H34N2O6S)

24 months

Anhui ANKE HENGYI Pharmaceutical Co., Ltd.

• Founded in:

  1991-02-11

• Address:

  New Town, Economic Development Zone, Tongling City, Anhui Province

• Tax NO.:

  9134070015110558XD

• Registered Funds:

  38 million yuan

• Website:

  Log in to view

• Email:

  Log in to view